- Home
- CVKD vs KALA Comparison
CVKD vs KALA Comparison
Compare CVKD & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- KALA
- Stock Information
- Founded
- CVKD 2022
- KALA 2009
- Country
- CVKD United States
- KALA United States
- Employees
- CVKD N/A
- KALA N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- KALA Health Care
- Exchange
- CVKD Nasdaq
- KALA Nasdaq
- Market Cap
- CVKD 29.5M
- KALA 26.2M
- IPO Year
- CVKD 2023
- KALA 2017
- Fundamental
- Price
- CVKD $12.18
- KALA $5.60
- Analyst Decision
- CVKD Strong Buy
- KALA Strong Buy
- Analyst Count
- CVKD 1
- KALA 3
- Target Price
- CVKD $32.00
- KALA $14.00
- AVG Volume (30 Days)
- CVKD 36.2K
- KALA 125.3K
- Earning Date
- CVKD 08-06-2025
- KALA 08-05-2025
- Dividend Yield
- CVKD N/A
- KALA N/A
- EPS Growth
- CVKD N/A
- KALA N/A
- EPS
- CVKD N/A
- KALA N/A
- Revenue
- CVKD N/A
- KALA N/A
- Revenue This Year
- CVKD N/A
- KALA N/A
- Revenue Next Year
- CVKD N/A
- KALA N/A
- P/E Ratio
- CVKD N/A
- KALA N/A
- Revenue Growth
- CVKD N/A
- KALA N/A
- 52 Week Low
- CVKD $5.70
- KALA $2.92
- 52 Week High
- CVKD $22.90
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- CVKD 49.98
- KALA 59.32
- Support Level
- CVKD $11.00
- KALA $5.56
- Resistance Level
- CVKD $13.56
- KALA $7.00
- Average True Range (ATR)
- CVKD 1.15
- KALA 0.72
- MACD
- CVKD 0.25
- KALA 0.08
- Stochastic Oscillator
- CVKD 80.97
- KALA 59.00
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.